There are currently 58 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Atopic Dermatitis participants are California, Florida, Texas and Ontario.
Ethnic Differences in Mechanisms of Action of Dupilumab
NCT05268107
Recruiting
Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD. This trial will determine differences in inflammatory responses to dupilumab between Caucasian, Asian, and African American patients with AD. The central hypothesis of this study is that ethnic di... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/18/2023
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Atopic Dermatitis
Register for Updates
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
NCT06055361
Recruiting
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)
Gender:
All
Ages:
18 years and above
Trial Updated:
09/20/2023
Locations: Arkansas Research Trials, North Little Rock, Arkansas +2 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
NCT05721937
Recruiting
The purpose of this observational study is to learn about the safety of abrocitinib (CIBINQO) in pregnant women and the offspring. The study is seeking participants who: Are currently or recently pregnant Receive at least one dose of CIBINQO at any time during pregnancy or prior to pregnancy OR have a diagnosis of moderate-to-severe atopic dermatitis All participants in this study will receive treatment according to routine care, as this is an observational study. The exposed group will consi... Read More
Gender:
Female
Ages:
0 years and above
Trial Updated:
08/10/2023
Locations: Pfizer, New York, New York
Conditions: Atopic Dermatitis
Register for Updates
Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
NCT05938478
Recruiting
The goal of this observational study is to learn about exposure to tralokinumab during pregnancy, as well as atopic dermatitis (AD) during pregnancy. The main question the study aims to answer is whether pregnant people who have been exposed to tralokinumab during pregnancy experience any differences in pregnancy and infant outcomes compared to women with atopic dermatitis who have not been exposed to tralokinumab during pregnancy. Participants are not required to take tralokinumab during the s... Read More
Gender:
Female
Ages:
All
Trial Updated:
07/03/2023
Locations: University of California San Diego (UCSD), La Jolla, California
Conditions: Atopic Dermatitis, Eczema
Register for Updates
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
NCT03936335
Recruiting
The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of infant outcomes (major congenital malformations [MCMs], small for gestational age [SGA]) in women with AD who are treated with dupilumab during pregnancy relative to women with AD who are not treated with dupilumab during pregnancy.
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
05/11/2023
Locations: Regeneron Research Site, Boston, Massachusetts
Conditions: Adverse Pregnancy Outcomes, Atopic Dermatitis
Register for Updates
Molecular Signatures of Cutaneous Dupilumab Response
NCT05858619
Recruiting
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/04/2023
Locations: University of California, San Francisco, San Francisco, California
Conditions: Atopic Dermatitis
Register for Updates
Assessment of the Effect of Coconut and Sunflower Seed Oil Derived Isosorbide Diseters and Colloidial Oatmeal
NCT05688735
Recruiting
The goal of this study is to compare coconut oil and sunflower seed oil derived isosorbide disesters and colloidal oatmeal, and observe their effect on pediatric atopic dermatitis among males and females aged 2-17.
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
04/12/2023
Locations: Integrative Skin Science and Research, Sacramento, California
Conditions: Atopic Dermatitis
Register for Updates
A Prospective Sample Collection Study Using Non-invasive Methods to Investigate Biomarkers in AD Patients
NCT04699695
Recruiting
This is a prospective, multicenter, sample collection study using DermTech's non-invasive skin collection kits to evaluate genomic biomarkers and microbiome information from pediatric and adult subjects with atopic dermatitis(AD). Samples collected will be analyzed to detect gene signatures and microbiome populations associated with AD and sub-populations of AD.
Gender:
All
Ages:
1 year and above
Trial Updated:
07/25/2022
Locations: Orit Markowitz, New York, New York +1 locations
Conditions: Atopic Dermatitis
Register for Updates
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT05048056
Recruiting
This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/04/2022
Locations: AkesoBio Investigative Site 2003, Little Rock, Arkansas +23 locations
Conditions: Atopic Dermatitis
Register for Updates
Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.
NCT05265234
Recruiting
The study is trying to answer the following question: "Can we use non-invasive imaging to evaluate the response of atopic dermatitis (eczema) to Dupixent (dupilumab)?"
Gender:
All
Ages:
18 years and above
Trial Updated:
02/22/2022
Locations: OptiSkin Medical, New York, New York
Conditions: Eczema, Atopic Dermatitis
Register for Updates